Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHASIT study
2022-000514-33Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in transitional cell carcinoma (TCC), sponsored by Erasmus MC. Primary endpoint: Pathological complete response rate. Started Apr 2022; status: active.
02
Drugs
avelumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2022-000514-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000514-33.